Product Name: Human CD79b / Ig B Antibody (Polatuzumab, Research Use)
Catalog Number: NBR-0141
Target Name: CD79b / Ig B
Trade Name: Polatuzumab
Antibody Drug Description: Polatuzumab vedotin (INN; brand name Polivy, is an antibody-drug conjugate or ADC designed for the treatment of cancer. The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: CD79b / Ig B
Synonyms: B29; Ig-Beta; IGB
Target Description: CD79B (CD79b Molecule) is a Protein Coding gene. Diseases associated with CD79B include Agammaglobulinemia 6, Autosomal Recessive and Agammaglobulinemia, Non-Bruton Type. Among its related pathways are Antigen activates B Cell Receptor (BCR) leading to generation of second messengers and Disease. Gene Ontology (GO) annotations related to this gene include transmembrane signaling receptor activity. An important paralog of this gene is CD79A.
Ensembl: ENSG00000007312
Uniprot: P40259